VRAX (Virax Biolabs Group) Stock Based Compensation: $0.13 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRAX Virax Biolabs Group Ltd VRAX
44 GF Score
Price $3.89
GF Value $3.63
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Virax Biolabs Group Stock Based Compensation?

Virax Biolabs Group VRAX +2.64% 44 Stock Based Compensation is $0.13 Mil as of Mar. 2026. GuruFocus rates VRAX with a GF Score™ of 44/100 and a GF Value™ of $3.63 (Fairly Valued). The stock has 3 warning signs investors should review.

Virax Biolabs Group's Stock Based Compensation for the six months ended in Mar. 2026 was $0.08 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $0.13 Mil.

Virax Biolabs Group Stock Based Compensation Related Terms

Virax Biolabs Group Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Virax Biolabs Group's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virax Biolabs Group Stock Based Compensation Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Stock Based Compensation
Get a 7-Day Free Trial 0.00 1.74 1.01 0.37 0.13

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.93 0.04 0.33 0.05 0.08
VRAX
44GF Score
Virax Biolabs Group Ltd VRAX
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Virax Biolabs Group Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.13 Mil.

What does a Stock Based Compensation of $0.13 Mil mean?
Virax Biolabs Group (VRAX) has a Stock Based Compensation of $0.13 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Virax Biolabs Group and its competitors.
Is Virax Biolabs Group's Stock Based Compensation too high?
Virax Biolabs Group's current Stock Based Compensation is $0.13 Mil. Overall, Virax Biolabs Group has a GF Score™ of 44/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's Stock Based Compensation compare to BBLG and PKTX?
Virax Biolabs Group's Stock Based Compensation of $0.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Virax Biolabs Group and its competitors. Virax Biolabs Group's current Stock Based Compensation is $0.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Fairly Valued. The stock's GF Value™ is $3.63, compared to a current price of $3.89 — trading 7.2% above its estimated fair value. The current Stock Based Compensation is $0.13 Mil. Virax Biolabs Group's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current Stock Based Compensation is $0.13 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virax Biolabs Group (VRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued. The current stock price of $3.89 is trading 7.2% above its estimated GF Value™ of $3.63. GuruFocus considers Virax Biolabs Group to be Fairly Valued.

Key valuation signals for VRAX:

  • Stock Based Compensation: $0.13 Mil
  • GF Value™: $3.63 vs. price of $3.89 (7.2% above fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virax Biolabs Group Business Description

Address Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
44GF Score

Get the complete analysis for VRAX

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.89
Price
$3.63
GF Value